




CBAS is coordinated by [Ibis Reproductive Health](#)



**Volume 12, Number 2**

**June 5, 2015**

The U.S. Food and Drug Administration (FDA) is now accepting comments from the public regarding possible reclassification of female condoms from a Class III to a Class II device, which would be the same classification as male condoms.

Reclassifying female condoms from a Class III to a Class II medical device would likely open the U.S. market to new products and expand options for protection from sexually transmitted infections, including HIV, and unintended pregnancy.

Please consider voicing your support. You or your organization can sign on to the comments being submitted by the National Female Condom Coalition (NFCC), or you can use the template below to submit your own.

- [Join the NFCC's comments to the FDA.](#) **Deadline: Wednesday, June 24**
- [Submit your own comments to the FDA.](#) [Modify the template and follow the instructions for online comments submission.](#) **Deadline: Monday, June 29**

Share these resources with your personal and professional networks so we can send a strong, clear message to the FDA that the U.S. needs and wants more prevention options.

## ABOUT US

Mission of CBAS

Established in 2004, the Cervical Barrier Advancement Society (CBAS) aims to raise the profile of cervical barrier methods, including diaphragms, caps, female condoms, and other devices, and to share the latest news and resources related to these methods.

CBAS contact information

For more information, contact Kate Grindlay, CBAS Executive Director, at [info@cervicalbarriers.org](mailto:info@cervicalbarriers.org).

CBAS is coordinated by Ibis Reproductive Health.



We welcome comments or suggestions for future newsletter items. Please contact [info@cervicalbarriers.org](mailto:info@cervicalbarriers.org).

**Note:** We are always updating our research listings on the CBAS website. Please contact us at [info@cervicalbarriers.org](mailto:info@cervicalbarriers.org) with study updates or information on new research related to cervical barriers or female condoms.

[Join CBAS](#)

- [Subscribe/Unsubscribe](#) to CBAS newsletter only
- [Archives](#) of the CBAS newsletter

*To comment on anything you read in the CBAS newsletter or to contribute a story, event, or news item, please [email CBAS](#).*

[Site Map](#) | [Privacy Policy](#) | [info@cervicalbarriers.org](mailto:info@cervicalbarriers.org)

